Our data suggest that both ABCB1 and ABCC11 are involved in the development of eribulin resistance in breast cancer cells and that eribulin or its metabolites might be substrates of ABCB1 and ABCC11. The gene discussed is ABCC11; the disease is breast carcinoma.